Rosalind Advisors
$266M 13F equity value
35 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Rosalind Advisors covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| DCTH | DELCATH SYSTEMS, INC. | 3,300,389 | $42M | 15.6% |
| FENC | FENNEC PHARMACEUTICALS INC | 3,188,001 | $34M | 12.9% |
| XERS | XERIS BIOPHARMA HOLDINGS INC | 2,908,981 | $23M | 8.7% |
| SVRA | SAVARA INC | 3,178,121 | $20M | 7.4% |
| VSTM | VERASTEM INC | 3,986,509 | $15M | 5.7% |
| XFOR | X4 PHARMACEUTICALS INC | 3,214,766 | $15M | 5.6% |
| EYPT | EYEPOINT PHARMACEUTICALS INC | 988,230 | $14M | 5.3% |
| HELP | CYBIN INC | 1,956,814 | $13M | 4.9% |
| VOR | VOR BIOPHARMA INC | 648,600 | $12M | 4.5% |
| PCVX | VAXCYTE INC | 200,000 | $12M | 4.4% |
Track Rosalind Advisors's 13F portfolio: $266M in reported holdings, 35 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}